NOVO NORDISK A S business relationships
Companies named in NOVO NORDISK A S’s 20-F filed 2026-02-04, and public companies whose annual reports name NOVO NORDISK A S. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.7 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: PeptidesGLP-1 & obesity
Named in NOVO NORDISK A S’s annual report 0
No company named in this filing matched a company in the map.
Companies whose annual reports name NOVO NORDISK A S 20
“...head and its collaborators, AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences, Ltd., as well as our collaborators...” SEC filing
“These include products that are being developed in collaboration with L undbeck, Novo Nordisk and” SEC filing
“This increase was primarily attributable to the continued growth of YORVIPATH global sales, partly offset by the recognition of a $100 million upfront payment in 2024 related to our exclusive license agreement with Novo Nordisk.” SEC filing
“In January 2025, we announced that our multi-product collaboration with Novo Nordisk for TransCon technology-based therapies in obesity and metabolic diseases continues and that the lead program TransCon Semaglutide, remains on track to enter the clinic as anticipated.” SEC filing
“Research Collaboration and License Agreement between Evotec International GmbH and Novo Nordisk A/S, dated July 8, 2020 (incorporated herein by reference to Exhibit 10.13 to the Company's Registration Statement on Form F-1 (File No. 333-260143), as amended, initially filed with the SEC on October 8,...” SEC filing
“BMS antiviral collaboration; Novo Nordisk cell therapy collaboration (total Deal Volume cannot be disclosed, > € 1bn)” SEC filing
“...ing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestations of AATD.” SEC filing
“Hoffman-La Roche Ltd and Hoffmann-La Roche Inc. (together "Roche"), Bristol Myers Squibb Company ("BMS"), and Novo Nordisk, and amounts we may receive under such collaborations; the sufficiency of our cash position to fund advancement of a broad pipeline and completion of our ongoing clinical trials...” SEC filing
“We are dependent on Novo Nordisk, and its third-party manufacturers if applicable, to manufacture clinical supplies of coramitug.” SEC filing
“Early-stage device-based technologies such as the SOMA and LUMI from the Novo Nordisk-MIT collaboration were reported to be in early clinical and preclinical stages, respectively.” SEC filing
“We entered into an exclusive license agreement with Novo Nordisk A/S in March 2025 under which we granted Novo” SEC filing
“The Company also concluded that the Novo Nordisk License Agreement is not a collaborative agreement under ASC 808, Collaborative Arrangements , as Novo Nordisk is responsible for all regulatory and commercialization activities for LX9851, as well as conducting any additional clinical trials required...” SEC filing
“Metabolic Diseases: Collaboration with Novo Nordisk” SEC filing
“The Company also agreed to promptly wind-down its research and development activities in connection with the license agreement and Novo Nordisk agreed to reimburse the Company for certain wind-down costs associated with the hold period.” SEC filing
“In November 2025, we agreed to a 12 month pause on our collaboration with Novo Nordisk.” SEC filing
“The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an out-licensing agreement.” SEC filing
“In July 2017, the Company signed an exclusive license agreement with Novo Nordisk A/S relating to avdoralimab.” SEC filing
“During 2025, we sold to Novo Nordisk Health Care AG the exclusive global rights in all indications to develop and commercialize zaltenibart, also known as OMS906, our antibody targeting mannan-binding lectin-associated serine protease-3 ("MASP-3"), the key activator of the alternative pathway of com...” SEC filing
“Concurrent with the closing of the Transaction, Novo Nordisk granted to us exclusive, worldwide, royalty-free, transferrable (solely in connection with a permitted assignment of the APLA), sublicensable (in accordance with the APLA), perpetual and irrevocable (except as set forth in the APLA) licens...” SEC filing
“We expect to continue to incur additional losses until such time as we generate significant revenue from the sale of YARTEMLEA or other commercial products or from our APLA with Novo Nordisk or other partnerships.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.